ERNA Ernexa Therapeutics Inc.
Price Chart
Executive Summary
Ernexa Therapeutics announced preclinical success for its lead candidate ERNA-101 in ovarian cancer, with plans to submit an IND in Q3 2026 and initiate a first-in-human trial in Q4 2026. The company highlighted upcoming milestones over the next 18 months, supported by a recent $10.5M financing, as it transitions to a clinical-stage biotech.
Actionable Insight
Traders should monitor upcoming IND submission (Q3 2026) and trial initiation (Q4 2026) as near-term catalysts. The $10.5M financing de-risks near-term execution, but further dilution is likely ahead of clinical data readout in 2027. Positive early data could drive significant upside given the company's small $6M market cap.
Key Facts
- Preclinical data show deep and durable tumor regressions with ERNA-101 in combination with PD-1 blockade in ovarian cancer models
- IND submission for ERNA-101 expected in Q3 2026; first-in-human Phase 1 trial to start in Q4 2026 for platinum-resistant ovarian cancer
- Company completed Pre-IND meeting with FDA and reduced G&A expenses by 61% YoY in 2025
- Recent $10.5 million financing supports advancement through key milestones
- Initial clinical data readout expected in 1H 2027, with potential Phase 2 advancement via co-development partner in 2H 2027
Financial Impact
$10.5 million in recent financing; no direct revenue or EPS impact yet as company remains pre-revenue
Risk Factors
- High risk associated with early-stage biotech: clinical trials may fail despite strong preclinical results
- Dilution risk as additional capital will likely be needed before 2027 data readout
- No guaranteed partnership or co-development deal in Phase 2
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
16d ago
|
Press Release
| $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $6.15 (−44.79%) |
|
May 6, 2026
5w ago
|
Press Release
| $6.04 $12.01 | ▲ +98.84% | ▲ +97.71% | $6.15 (+1.82%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $5.00 $0.2200 | ▼ −95.60% | ▼ −99.54% | $6.15 (+23.00%) |
|
Mar 24, 2026
11w ago
|
S-3/A
| $5.25 $0.2100 | ▲ +96.00% | ▲ +95.76% | $6.15 (−17.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access